SOHO State of the Art Updates and Next Questions | Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway-Reference-Cited by-同舟云学术

SOHO State of the Art Updates and Next Questions | Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway

Published:2022-09 Issue:9 Volume:22 Page:652-658
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Maiti Abhishek^ORCID,Carter Bing Z.,Andreeff Michael,Konopleva Marina Y.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference82 articles.

1. Azacitidine and venetoclax in previously untreated acute myeloid leukemia;DiNardo;N Engl J Med,2020

2. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia;DiNardo;J Clin Oncol,2021

3. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia;DiNardo;Blood,2019

4. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial;DiNardo;Lancet Haematol,2020

5. Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy;Chua;J Clin Oncol,2020

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia;Leukemia Research;2024-09

2. Venetoclax Resistance in Acute Myeloid Leukemia;Cancers;2024-03-08

3. Nucleic acid therapeutics as differentiation agents for myeloid leukemias;Leukemia;2024-02-29

4. Screen and evaluate the prognostic capacity and clinical value of Necroptosis-related Genes in acute myeloid leukemia;2024-02-22

5. Redefining Cancer Therapy: Toward BCL-XL/BCL-2 Dual Inhibitors with Diminished Platelet Toxicity;ACS Medicinal Chemistry Letters;2023-08-22